01 March 2007
A novel vitamin C preparation enhances neurite formation and fibroblast adhesion and reduces xenobiotic-induced T-cell hyperactivation
Benjamin S. Weeks, Pedro P. PerezMed Sci Monit 2007; 13(3): BR51-58 :: ID: 475504
Abstract
Background: Vitamin C (ascorbic acid, ascorbate) has been shown to enhance neurite outgrowth, promote fi broblast adhesion during wound healing, and reduce xenobiotic-induced leukocyte hyperactivity and
infl ammatory damage. In this study, a comparison was made between Ester-C® and PureWay-C™ on these various cellular activities.
Material/Methods: PC12 cells were stimulated to form neurites with nerve growth factor, NIH 3T3 fi broblasts were seeded on fi bronectin and H9 T-cells were stimulated to aggregate with the pyrethroid pesticide
bifenthrin. The rate of neurite formation, fi broblast adhesion and T-cell homotypic aggregation was then measured in the absence and presence of various formulations of vitamin C including Ester-C® and PureWay-C™.
Results: With PureWay-C™ treatment, 12% of PC12 cells extended neurites within one hour of treatment and 45% of the cells extended neurites by hour nine. With Ester-C®, 0% and 15% extended neurites at one and nine hours, respectively. NIH-3T3 fi broblast adhesion to fi bronectin was enhanced
by 4.7-fold with a 30 minute PureWay-C™ treatment while Ester-C® increased fi broblast adhesion by only 1.5 fold. Further, PureWay-C™ reduced pesticide-mediated T-cell homotypic aggregation
by 83% within 30 minutes of treatment while the reduction seen with Ester-C® was only 33%.
Conclusions: These data confi rm the previous observations that vitamin C supplementation can promote neurite outgrowth, increase fi broblast adhesion and reduce xenobiotic induce immunocytes aggregation.
More importantly, these data show that PureWay-C™ has a faster and greater benefi cial effect on these parameters when compared to other vitamin C formulations.
Keywords: Xenobiotics - pharmacology, T-Lymphocytes - immunology, Pyrethrins - pharmacology, Phytohemagglutinins - pharmacology, Neurites - drug effects, Nerve Growth Factors - pharmacology, NIH 3T3 Cells, Cell Adhesion - drug effects, Lymphocyte Activation - immunology, Fibronectins - metabolism, Fibroblasts - drug effects, Dose-Response Relationship, Drug, Cell Aggregation - drug effects, Ascorbic Acid - pharmacology
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952